Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Add To Watchlist

Recent & Breaking News (NDAQ:GILD)

Gilead Sciences' New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA

Business Wire April 21, 2014

Gilead Sciences to Release First Quarter 2014 Financial Results on Tuesday, April 22, 2014

Business Wire April 15, 2014

Gilead's Sovaldi® Demonstrates Efficacy and Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease

Business Wire April 11, 2014

Nasdaq Plummets Over 3 Percent; DJIA, S&P Down as Well

Equities.com April 10, 2014

VIDEO: Do Expensive Hep C Drugs Like Sovaldi Actually Reduce Costs?

Equities.com April 10, 2014

Gilead Announces Results from Study of Sovaldi® for Retreatment of Chronic Hepatitis C in Patients Not Cured with Prior Antiviral Therapy

Business Wire April 10, 2014

Gilead Announces Phase 2 Results for Two Investigational All-Oral Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C

Business Wire April 10, 2014

How Did High Flyers Turn into Soul Searchers? Maxim Analyst Jason Kolbert on the Highs and Lows of Biotech Valuations

Equities.com April 9, 2014

High flying biotech and tech stocks drop as investors seek safety

Canadian Press April 8, 2014

Over 1 Percent Losses for DJIA, S&P, NASDAQ as Stocks Continue to Fall

Equities.com April 7, 2014

Gilead's (GILD) Blockbuster Hepatitis-C Drug Sovaldi Steps Up Race

Equities.com April 7, 2014

Gilead Announces U.S. FDA Priority Review Designation for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Chronic Hepatitis C Genotype 1 Infection

Business Wire April 7, 2014

Biotech ETFs Decline a Sign of a Bursting Bubble?

Equities.com April 3, 2014

Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan

Business Wire April 2, 2014

Wall Street Rallies as Stocks Gain on Less Hawkish Yellen

Equities.com March 31, 2014

Did Henry Waxman's Letter to Gilead (GILD) Mark the Bursting of the Biotech Bubble?

Equities.com March 31, 2014

Gilead Announces Settlement Method for 1.00% Convertible Senior Notes Due 2014

Business Wire March 28, 2014

European Medicines Agency Validates Gilead's Marketing Application for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Chronic Hepatitis C Infection

Business Wire March 27, 2014

Idenix Pharmaceuticals Intends to Appeal Norway District Court Decision Regarding Patent Invalidity Case

GlobeNewswire March 24, 2014

King: How the Oncology Drug Development Machine Builds Biotech Wealth

Equities.com March 17, 2014